Ruth He, MD, discusses the current treatment options for unresectable hepatocellular carcinoma.
EP. 1: Frontline Systemic Therapy in HCC Patients
Ruth He, MD, highlights factors that influence her use of frontline systemic therapy in patients with unresectable hepatocellular carcinoma.
Watch
EP. 2: Atezolizumab and Bevacizumab in the Phase 3 IMbrave150 Trial
Ruth He, MD, discusses major takeaways from the phase 3 IMbrave150 trial of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma.
EP. 3: Approval of Frontline Atezolizumab + Bevacizumab Treatment
Ruth He, MD, discusses the approval of frontline atezolizumab-bevacizumab and its relation to subsequent treatment of patients with unresectable hepatocellular carcinoma.
EP. 4: Unmet Needs of HCC Management
Ruth He, MD, acknowledges the current struggles experts face in combatting unresectable hepatocellular carcinoma.
EP. 5: Emerging Combination Therapies for HCC
Ruth He, MD, discusses potential options for physicians in their treatment of unresectable hepatocellular carcinoma.
EP. 6: Advice on Future Treatment of HCC
Ruth He, MD, grants advice on how to treat patients with unresectable hepatocellular carcinoma.
